Trial Profile
A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Ixabepilone (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 04 Jul 2012 Planned number of patients changed from 260 to 320 as reported by European Clinical Trials Database record.
- 08 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Aug 2010 Planned end date changed from 1 Feb 2011 to 1 Aug 2011 as reported by ClinicalTrials.gov.